Author

Shannon Thomson

The University of Sydney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:benchmarking· 3 Assay:proteomics· 3 Approach:statistical model· 3 Research Focus:differential expression· 2 Approach:machine learning (classical)· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1

Frequent Co-Authors

Caitlin A. FinneyiD· 5 shared Artur ShvetcoviD· 4 shared David Alexander BrowniD· 2 shared Heather WilkinsiD· 2 shared Russell Howard SwerdlowiD· 2 shared Ann‐Na ChoiD· 1 shared Chad M SlawsoniD· 1 shared Finula I. IsikiD· 1 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersNeuroscience

Caitlin A. FinneyORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Patient cerebral organoids capture Alzheimers disease proteomic biomarkers and drug targets

Shannon Thomson, Xinran C Li, Sophie Walker, Tiffany C. Y. Tang, Mark Evan Graham, Sam W.Z. Olechnowicz, Rory J. Bowden, Katherine A. Waugh, Chad M Slawson, Jeffrey Murray Burns, Russell Howard Swerdlow, Heather Wilkins, Artur Shvetcov, Caitlin A. Finney

The paper benchmarks proteomic biomarkers and drug targets in patient-derived cerebral organoids against clinical cohorts, finding they detect most candidates and replicate disease changes in a quarter of reproducible markers.

bioRxiv · Jun 26, 2026 · PreprintNeuroscience

Adding iPSC donor lines does not adequately control for genetic heterogeneity

Artur Shvetcov, Shannon Thomson, Caitlin A. Finney

This paper evaluates the adequacy of using 3-5 iPSC donor lines to control for genetic heterogeneity and finds that these sample sizes are insufficient for reliable detection or estimation of donor-level variance.

bioRxiv · Apr 26, 2026 · PreprintBioengineering

APOE ε4 defines a systemic immune endophenotype independent of clinical trajectory in amyotrophic lateral sclerosis

Artur Shvetcov, Shannon Thomson, Sterling Kwan, Terri G. Thompson, Jeffery D. Rothstein, Caitlin A. Finney

This study identifies an APOE ε4-associated systemic immune proteomic signature in ALS that predicts disease progression independently of clinical features.

bioRxiv · Feb 4, 2026 · PreprintNeuroscience

Cerebrospinal fluid proteome profiling using machine learning shows a unique protein signature associated with APOE4 genotype

Artur Shvetcov, Shannon Thomson, Ann‐Na Cho, Heather Wilkins, Joanne H. Reed, Russell Howard Swerdlow, David Alexander Brown, the Alzheimer’s Disease Neuroimaging Initiative, Caitlin A. Finney

This study identifies an APOE4-specific cerebrospinal fluid proteome signature using machine learning, independent of Alzheimer's disease diagnosis and associated with increased risk of cognitive impairment.

Aging Cell · Dec 25, 2024Peer-reviewedNeuroscience

A Systematic Review of the Neuroprotective Role and Biomarker Potential of GDF15 in Neurodegeneration

Finula I. Isik, Shannon Thomson, John F. Cueto, Jessica Spathos, Samuel N. Breit, Vicky Wang-Wei Tsai, David Alexander Brown, Caitlin A. Finney

This review evaluates GDF15's neuroprotective role and biomarker potential in neurodegeneration and neurotrauma, highlighting its upregulation and therapeutic benefits in preclinical models.

bioRxiv · Jul 7, 2024 · PreprintNeuroscience